Company Performance - Medpace's stock closed at $582.48, reflecting a decrease of -1.79% from the previous day, underperforming compared to the S&P 500's daily loss of 0.43% [1] - Over the last month, Medpace's shares have increased by 5.59%, outperforming the Medical sector's loss of 2.36% and the S&P 500's gain of 0.89% [1] Upcoming Earnings - Medpace is set to disclose its earnings on February 9, 2026, with analysts expecting earnings of $4.18 per share, indicating a year-over-year growth of 13.9% [2] - The consensus estimate for revenue is projected at $681.17 million, representing a growth of 26.94% compared to the same quarter last year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $14.8 per share and revenue of $2.5 billion, reflecting changes of +17.18% and 0% respectively from the prior year [3] - Recent changes to analyst estimates indicate a positive outlook for Medpace, as upward revisions are often seen as a sign of optimism regarding business trends [3] Valuation Metrics - Medpace has a Forward P/E ratio of 35.67, which is a premium compared to the industry average Forward P/E of 15.73 [6] - The company has a PEG ratio of 1.99, compared to the Medical Services industry's average PEG ratio of 1.77 [6] Industry Context - The Medical Services industry, which includes Medpace, ranks 178 in the Zacks Industry Rank, placing it in the bottom 28% of over 250 industries [7] - The Zacks Industry Rank evaluates the performance potential of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Giverny Capital Asset Management, LLC, an investment management company, recently published its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. The Portfolio returned 0.01% compared to 2.66% for the S&P 500. YTD, the fund returned 12.58% compared to 17.88% for the Index. The firm faced a challenging fourth quarter and calendar year, despite solid appreciation. The outperformance of a few large technology companies has negatively impacted performance, given the portfolio's und ...

Company Performance - Medpace's stock closed at $588.05, down 3.01%, underperforming the S&P 500's gain of 0.03% on the same day [1] - Over the past month, Medpace's stock has increased by 6.02%, outperforming the Medical sector's slight loss of 0.01% and the S&P 500's gain of 0.6% [1] Upcoming Earnings - Medpace is set to release its earnings report on February 9, 2026, with an expected EPS of $4.18, reflecting a 13.9% increase year-over-year [2] - Revenue is anticipated to reach $681.17 million, indicating a 26.94% rise compared to the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $14.8 per share and revenue of $2.5 billion, representing increases of 17.18% and no change, respectively, from the previous year [3] - Recent revisions to analyst forecasts for Medpace are crucial as they reflect short-term business trends and can indicate analysts' positive outlook on the company's health and profitability [3] Valuation Metrics - Medpace currently has a Forward P/E ratio of 36.47, which is significantly higher than the industry average Forward P/E of 16.37 [5] - The company has a PEG ratio of 2.04, compared to the industry average PEG ratio of 1.92 [6] Industry Ranking - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 188, placing it in the bottom 24% of over 250 industries [6] - The Zacks Industry Rank evaluates the performance of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Investment management company Vulcan Value Partners recently released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. All the strategies of Vulcan Value Partners delivered positive results in the year. The Large Cap Composite (Net) returned -1.5% in Q4 and 7.9% YTD, the Small Cap Composite (Net) gained 3.2% in Q4 and 9.5% YTD, The Focus Composite (Net) retuned 0.1% in Q4 and 7.1% YTD, Focus Plus Composite (Net) returned 0.1% in Q4 and 6.2% YTD and the All-Cap Composite ...

Company Performance - Medpace (MEDP) closed at $616.45, marking a +1.32% move from the prior day, outperforming the S&P 500's daily loss of 0.53% [1] - The stock has risen by 8.89% in the past month, leading the Medical sector's gain of 0.09% and the S&P 500's gain of 2.06% [1] Upcoming Earnings - Medpace's earnings report is set to be unveiled on February 9, 2026, with projected earnings per share (EPS) of $4.18, reflecting a 13.9% increase from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projecting net sales of $681.17 million, up 26.94% from the year-ago period [2] Full Year Estimates - Analysts expect earnings of $14.8 per share and revenue of $2.5 billion for the full year, marking changes of +17.18% and 0%, respectively, from last year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Medpace are important as they indicate changing near-term business trends, with positive alterations signifying analyst optimism regarding the business and profitability [4] Valuation Metrics - Medpace is currently traded at a Forward P/E ratio of 36.6, which is a premium compared to its industry average Forward P/E of 15.3 [7] - The company has a PEG ratio of 2.04, compared to the Medical Services industry's average PEG ratio of 1.91 [7] Industry Ranking - The Medical Services industry holds a Zacks Industry Rank of 194, positioning it in the bottom 21% of all 250+ industries, indicating weaker performance compared to higher-ranked industries [8]

Industry Overview - The Medical Services sector is rapidly evolving due to digital health advancements, value-based care adoption, and a focus on patient-centric solutions [1] - The global healthcare analytics market is projected to grow from $56.64 billion in 2025 at a CAGR of 22.7% through 2035, benefiting payers, providers, and analytics vendors [1] - The industry includes various service providers such as pharmacy benefit managers, contract research organizations, and healthcare workforce solution providers, transitioning from volume-based to value-based care [3] Key Trends - The U.S. digital health market is expected to grow from $92.08 billion in 2025 to $248.11 billion by 2034, with a CAGR of 11.6% [4] - The global big data in healthcare market is valued at $110.97 billion in 2025, projected to grow at a CAGR of 19.2% from 2026 to 2035 [4] - Companies adopting AI technologies have seen a 50% reduction in treatment costs and over 50% improvement in patient outcomes [4] Workforce Challenges - A projected healthcare worker shortage of 100,000 by 2028, including a shortfall of 73,000 nursing assistants, is expected to elevate labor costs [2][5] - The WHO estimates a shortfall of 11 million physicians, particularly in low-income countries, emphasizing the need for workforce expansion [5] - Total hospital expenses increased by 5.1% in 2024, significantly outpacing the overall inflation rate of 2.9% [5] Company Highlights - **Medpace Holdings (MEDP)**: Expected earnings growth rate of 17.2% in 2025, with revenues projected to rise by 18.7% from 2024 [19][20] - **Enhabit, Inc. (EHAB)**: Anticipated earnings surge of 161.9% in 2025, with revenue growth of 2.3% [23][24] - **Progyny (PGNY)**: Projected earnings increase of 9.8% in 2025, with revenues expected to grow by 9.2% [26][27] Performance Metrics - The Medical Services industry has gained 6.8% over the past year, in line with the Medical sector, but lagged behind the S&P 500's 19.3% increase [10] - The industry is currently trading at a forward P/E of 16.9X, compared to the S&P 500's 23.3X and the sector's 21.6X [14]

Company Performance - Medpace (MEDP) closed at $561.65, reflecting a -1.27% change from the previous day, underperforming the S&P 500's loss of 0.74% [1] - Prior to the latest trading session, Medpace shares had declined by 2.54%, contrasting with the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Earnings Forecast - Medpace is expected to report an EPS of $4.18, representing a 13.9% increase from the same quarter last year [2] - Revenue is forecasted to be $681.17 million, indicating a growth of 26.94% compared to the corresponding quarter of the prior year [2] Full Year Estimates - For the full year, analysts project earnings of $14.8 per share and revenue of $2.5 billion, reflecting increases of +17.18% and +18.68% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Medpace are important as they indicate shifts in near-term business trends, with positive revisions suggesting optimism about the business outlook [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns Medpace a rank of 2 (Buy) [6] Valuation Metrics - Medpace has a Forward P/E ratio of 38.45, which is a premium compared to the industry average Forward P/E of 15.5 [7] - The company also has a PEG ratio of 2.15, compared to the Medical Services industry's average PEG ratio of 1.72 [7] Industry Context - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [8] - Historically, the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Wasatch Global Investors, an asset management company, released its third-quarter 2025 “Wasatch Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. US small-cap equities rallied strongly in the third quarter. The Fed Reserve’s interest rate cut supported the rally. However, the fund-Investor Class struggled to keep up with the rally and ended the period down -3.17% vs. 12.19% gain for the Russell 2000 Growth Index. In addition, please check the fund’s top five holdings t ...

Group 1 - Giverny Capital Asset Management reported a third-quarter 2025 return of 6.78%, underperforming the S&P 500 which returned 8.12% [1] - Year-to-date, the fund's return is 12.57%, compared to 14.83% for the S&P 500 index [1] - The fund's top 5 holdings were highlighted as key investment picks for 2025 [1] Group 2 - Medpace Holdings, Inc. (NASDAQ:MEDP) is identified as a significant investment, with a one-month return of -8.89% and a 52-week gain of 60.60% [2] - As of December 08, 2025, Medpace's stock closed at $549.17 per share, with a market capitalization of $15.47 billion [2] - The company specializes in clinical research and provides services for early-stage biopharmaceutical companies conducting clinical trials [3] Group 3 - Giverny Capital Asset Management acquired shares in Medpace Holdings, Inc. at approximately $381 last year, indicating confidence in the company's growth potential [3] - The investment decision was supported by insights from partners in Montreal who had a deep understanding of Medpace [3] - The company plays a crucial role in helping start-ups with promising drug compounds conduct trials to demonstrate efficacy [3]

Core Thesis - Medpace Holdings, Inc. is positioned as a strong investment opportunity due to its operational execution, strategic capital allocation, and market share growth, which the market has not fully recognized yet [1][2][5] Financial Performance - In Q2 2025, Medpace reported revenue of $603.3 million, reflecting a year-over-year increase of 14.2%, and EBITDA of $130.5 million with a margin of 21.6% [2] - The company has engaged in significant share repurchases, deploying $518.5 million to buy back 1.75 million shares, leaving only $46 million in cash [2][5] - Year-to-date buybacks total $913 million, showcasing the company's commitment to returning cash to shareholders [5] Competitive Advantage - Medpace offers a fully integrated suite of clinical research services, which enhances trial execution speed and reliability while reducing risk, distinguishing it from competitors that rely on acquisitions or outsourcing [3] - The company has achieved a 12.6% increase in net new business awards, indicating growing market share despite a challenging biotech funding environment [3] - Medpace's focus on risk mitigation and execution certainty makes it particularly appealing to mid-cap biotech clients [4] Future Outlook - Guidance for 2025 projects revenue between $2.42 billion and $2.52 billion, with EBITDA expected to be between $515 million and $545 million, indicating sustainable growth [4] - Continued investment in AI-driven patient recruitment and analytics is expected to create barriers to entry and enhance client retention [4] Market Recognition - The stock has appreciated approximately 93.62% since previous bullish coverage, driven by operational execution and client retention [6] - Recent aggressive buybacks and strong Q2 performance are emphasized as key factors in the company's positive outlook [6]